EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Response to RAF/MEK/ERK Inhibitors in Patients with RAS-Altered and Wild-Type Tumors

Mohamed A Gouda iD, Heather Lin, Lei Kang, Hung Le, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp, Apostolia Tsimberidou, Aung Naing, Sarina A Piha-Paul, Paula Pohlmann iD, Jordi Rodon und 3 weitere

Journal of Immunotherapy and Precision Oncology · 29.09.2026 · 9 (4) · 147-152

DOI: 10.36401/jipo-25-38 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, erschienen am 29.09.2026. Verfasst von Mohamed A Gouda und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

MAPKRASresponse

Autor:innen und Institutionen

  • Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Biostatistics, Division of Discovery Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Mohamed A Gouda, Paula Pohlmann, David S Hong

Förderung

  • NCI NIH HHS

Zitieren

APA

Gouda, M. A., Lin, H., Kang, L., Le, H., Dumbrava, E. E., Fu, S., Karp, D. D., Tsimberidou, A., Naing, A., Piha-Paul, S. A., Pohlmann, P., Rodon, J., Yap, T. A., Meric-Bernstam, F., & Hong, D. S. (2026). Response to RAF/MEK/ERK Inhibitors in Patients with RAS-Altered and Wild-Type Tumors. Journal of Immunotherapy and Precision Oncology, 9(4), 147-152. https://doi.org/10.36401/jipo-25-38

Vancouver

Gouda MA, Lin H, Kang L, Le H, Dumbrava EE, Fu S, et al. Response to RAF/MEK/ERK Inhibitors in Patients with RAS-Altered and Wild-Type Tumors. Journal of Immunotherapy and Precision Oncology. 2026;9(4):147-152. doi:10.36401/jipo-25-38

BibTeX
@article{Gouda2026,
  author = {Gouda, Mohamed A and Lin, Heather and Kang, Lei and Le, Hung and Dumbrava, Ecaterina E and Fu, Siqing and Karp, Daniel D and Tsimberidou, Apostolia and Naing, Aung and Piha-Paul, Sarina A and Pohlmann, Paula and Rodon, Jordi and Yap, Timothy A and Meric-Bernstam, Funda and Hong, David S},
  title = {Response to RAF/MEK/ERK Inhibitors in Patients with RAS-Altered and Wild-Type Tumors},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2026},
  volume = {9},
  number = {4},
  pages = {147--152},
  doi = {10.36401/jipo-25-38}
}
Kostenlos starten →